KLRC1 and neoplasm: To further investigate how tumor‐specific Tex cells respond to NKG2A blockade, congenically marked CD45.1+ P14 cells were transferred into B16F10‐GP cell‐engrafted C57BL/6 recipients, which were subsequently administrated with anti‐NKG2A‐blocking mAb or anti‐PD‐L1‐blocking mAb or anti‐NKG2A/anti‐PD‐L1‐blocking mAbs or control mAb on day 6, 9, and 12 (Figure 4C).